NUAgo Therapeutics is redefining the precision approach in cancer therapeutics. We are a pre-clinical stage company developing single-construct short RNAs that target dozens of critical cancer essential genes in systemic delivery platform that kill tumors specifically without observed toxicity in normal tissues. No longer bound to the treatment restrictions imposed due to patient and tumor heterogeneity, NUAgo's short RNAs offer the promise shift to potentially shift cancer therapy toward a chronic-like condition with periods of complete response or tumor elimination. Reach out to us if you would like to learn more.
Company Details
- Employees
- 5
- Founded
- -
- Address
- Chicago, Il, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://nuagotherapeutics.com
- Keywords
- London.
- HQ
- Chicago, IL
Nuago Therapeutics Questions
Nuago Therapeutics's website is https://nuagotherapeutics.com
Nuago Therapeutics's LinkedIn profile is https://www.linkedin.com/company/nuago-therapeutics
Nuago Therapeutics has
5 employees.
View email and phone details for 5
employees at Nuago Therapeutics.
Nuago Therapeutics's industry is
Biotechnology Research
Nuago Therapeutics's top competitors are
Syenex,
Boltos,
Oxford Cancer Biomarkers,
Acorn Genetics,
Mpc Therapeutics,
Zylem Biosciences,
Ots Capital,
Yobee,
Plutus Investment Group Llp,
Varchas Biotechnologies, Inc..
Nuago Therapeutics's categories are Biotechnology Research
Nuago Therapeutics's founding year is 2020
